Skip to main content
. 2022 Jul 19;12(7):110. doi: 10.1038/s41408-022-00704-7

Fig. 4. Targeted loss of BRD9 protein inhibits ALL cell proliferation and cell cycle progression and decreases viability.

Fig. 4

A Proliferation assays: ALL cell lines treated with QA-68. 6-day assay. B Effects of QA-68 on BRD9 expression in ALL cell lines. 24-h assay. C Effects of QA-68 on RS4;11 cell cycle progression. 6-day assay. D Effects of QA-68 SEM cell apoptosis. 6-day assay. E, left panel Proliferation of NALM6 control cells and doxycycline-inducible BRD9 KD NALM6 cells + /-doxycycline. 4-day assay. Asterisks indicate statistical significance. t-test, 4-day: NALM6 control (-dox):NALM6 control (+dox) (P = 0.377); NALM6 BRD9 KD#2 (-dox):NALM6 BRD9 KD#2 (+dox) (P < 0.0001); NALM6 BRD9 KD#5 (-dox):NALM6 BRD9 KD#5 (+dox) (P = 0.0212). (E, right panel) BRD9 expression in NALM6 control cells and doxycycline-inducible BRD9 KD NALM6 cells + /-doxycycline. F, left panel Proliferation of SEM control cells and doxycycline-inducible BRD9 KD SEM cells + /-doxycycline. 4- and 6-day assays. t-test, 4-day: SEM control (-dox):SEM control (+dox) (P = 0.2879); SEM BRD9 KD#2 (-dox):SEM BRD9 KD#2 (+dox) (P = 0.0107); SEM BRD9 KD#5 (-dox):SEM BRD9 KD#5 (+dox) (P = 0.0004). t-test, 6-day: SEM control (-dox):SEM control (+dox) (P = 0.1924); SEM BRD9 KD#2 (-dox):SEM BRD9 KD#2 (+dox) (P = 0.0006); SEM BRD9 KD#5 (-dox):SEM BRD9 KD#5 (+dox) (P = 0.0003). (F, right panel) BRD9 expression in SEM control cells and doxycycline-inducible BRD9 KD SEM cells + /-doxycycline. DOX, 1 µg/ml; DMSO, 0.1%. G Proliferation assays: Primary ALL1 cells treated with QA-68 and EA-89 for 4 days. H Proliferation assays: Normal bone marrow cells (sample #2) and primary ALL3 cells treated with QA-68 (left panel), dBRD9-A (middle panel), or EA-89 (right panel). 6-day assay. RS4;11 cells were tested as a positive control. I Treatment of primary ALL-3 cells with QA-68 alone, doxorubicin alone, or a combination. 6-day assay.